These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37831397)

  • 21. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
    Yamin D; Atkins KE; Remy V; Galvani AP
    Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
    Milne RJ; Grimwood K
    Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
    Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
    Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
    Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of the introduction of rotavirus vaccine in Hong Kong.
    Yeung KHT; Lin SL; Clark A; McGhee SM; Janusz CB; Atherly D; Chan KC; Nelson EAS
    Vaccine; 2021 Jan; 39(1):45-58. PubMed ID: 33221066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
    Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
    J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of rotavirus vaccination in children of Bhutan.
    Pempa ; Luz ACG; Luangasanatip N; Kingkaew P; Adhikari D; Isaranuwatchai W; Choiphel D; Pecenka C; Debellut F
    Vaccine; 2020 Jul; 38(32):5049-5059. PubMed ID: 32522415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of Rotavirus vaccination in Vietnam.
    Kim SY; Goldie SJ; Salomon JA
    BMC Public Health; 2009 Jan; 9():29. PubMed ID: 19159483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia.
    Reyes JF; Wood JG; Beutels P; Macartney K; McIntyre P; Menzies R; Mealing N; Newall AT
    Vaccine; 2017 Jan; 35(2):345-352. PubMed ID: 27916411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The economic impact of the introduction of universal rotavirus vaccination on rotavirus gastroenteritis related hospitalisations in children in Ireland.
    Murphy A; Kirby A; De Blasio F
    Vaccine; 2023 Apr; 41(16):2656-2663. PubMed ID: 36948981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
    Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
    Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of introducing a rotavirus vaccine in developing countries: the case of Mexico.
    Valencia-Mendoza A; Bertozzi SM; Gutierrez JP; Itzler R
    BMC Infect Dis; 2008 Jul; 8():103. PubMed ID: 18664280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fourteen years' clinical experience and the first million babies protected with human live-attenuated vaccine against rotavirus disease in Italy.
    Bonanni P; Conforti G; Franco E; Gabutti G; Marchetti F; Mattei A; Prato R; Vitali Rosati G; Vitale F
    Hum Vaccin Immunother; 2021 Nov; 17(11):4636-4645. PubMed ID: 34370615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of rotavirus vaccine use in Asia and the Pacific regions: challenges and future prospects.
    Buchy P; Chen J; Zhang XH; Benninghoff B; Lee C; Bibera GL
    Expert Rev Vaccines; 2021 Dec; 20(12):1499-1514. PubMed ID: 33275065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries.
    Marijam A; Schuerman L; Izurieta P; Pereira P; Van Oorschot D; Mehta S; Ota MO; Standaert B
    Hum Vaccin Immunother; 2022 Dec; 18(7):2135916. PubMed ID: 36507685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants.
    Kulkarni PS; Desai S; Tewari T; Kawade A; Goyal N; Garg BS; Kumar D; Kanungo S; Kamat V; Kang G; Bavdekar A; Babji S; Juvekar S; Manna B; Dutta S; Angurana R; Dewan D; Dharmadhikari A; Zade JK; Dhere RM; Fix A; Power M; Uprety V; Parulekar V; Cho I; Chandola TR; Kedia VK; Raut A; Flores J;
    Vaccine; 2017 Oct; 35(45):6228-6237. PubMed ID: 28967523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Economic evaluation of routine infant rotavirus immunisation program in Japan.
    Hoshi SL; Kondo M; Okubo I
    Hum Vaccin Immunother; 2017 May; 13(5):1115-1125. PubMed ID: 27763810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rotavirus vaccine RIX4414 (Rotarix™): a pharmacoeconomic review of its use in the prevention of rotavirus gastroenteritis in developed countries.
    Plosker GL
    Pharmacoeconomics; 2011 May; 29(5):439-54. PubMed ID: 21504245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of rotavirus vaccination: an important step of the introduction to the national immunization program in Thailand.
    Rochanathimoke O; Riewpaiboon A; Praditsitthikorn N; Tharmaphornpilas P; Jiamsiri S; Thavorncharoensap M; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):811-819. PubMed ID: 34008471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.